구조모아 (StructureMoa)항암 chemical structure spider web
방문EpizymeInc.
Auto-discovered from ClinicalTrials.gov (20 linked trials). 선택한 코호트에서 보고된 효능: ORR 87.5% (ClinicalTrials.gov NCT03677141).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FRα
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
humanized NOD/Shi-scid, IL-2Rγnull (huNOG) mice were used for an in vivo study
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
구조화 데이터
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
bypassing MHC presentation
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
FRα · CD20 RO% was high
, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA)
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were more frequently reported i
CD20 RO% was high
bypassing MHC presentation
구조화 데이터
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
EpizymeInc.
Auto-discovered from ClinicalTrials.gov (20 linked trials). 선택한 코호트에서 보고된 효능: ORR 87.5% (ClinicalTrials.gov NCT03677141).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FRα
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
humanized NOD/Shi-scid, IL-2Rγnull (huNOG) mice were used for an in vivo study
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
구조화 데이터
novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas
bypassing MHC presentation
bispecific antibodies: a pharmacovigilance study using FDA adverse eve
FRα · CD20 RO% was high
, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA)
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were more frequently reported i
CD20 RO% was high
bypassing MHC presentation
구조화 데이터
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.